数据显示,再鼎医药今年一季度营收为1.065亿美元,同比增长22%;经营亏损收窄20%至5630万美元。再鼎医药预计今年全年营收有望达到5.6亿美元至5.9亿美元,并有望在今年第四季度实现盈利。5月9日,再鼎医药股价报收23.6港元,涨5.59%。预计年底实现盈利再鼎医药年初营收增长主要来自已经商业化的产品,卫伟迦、则乐和纽再乐销售增长的驱动。其中,卫伟迦及卫力迦今年第一季度收入净额达1810...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.